Asia Pacific Low Molecular Weight Heparin Market is expected to reach US$ 1,232.57 Million by 2028


PRESS RELEASE BY The Insight Partners 09 Feb 2022

Share this press on


Deep Vein Thrombosis Segment to Dominate Asia Pacific Low Molecular Weight Heparin Market during 2019–2028

According to The Insight Partners market research study on “Asia Pacific Low Molecular Weight Heparin Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Packaging, Application, and End User,” is expected to reach US$ 1,232.57 million by 2028 from US$ 756.47 million in 2021. The market is estimated to grow at a CAGR of 7.2% from 2021 to 2028. Developments by companies is the major factor driving the growth of the Asia Pacific low molecular weight heparin market. However, adverse issues of low molecular weight heparin during treatment may hinder the growth of Asia Pacific low molecular weight heparin market. The report provides trends prevailing in the Asia Pacific low molecular weight heparin market along with the drivers and restraints pertaining to the market growth.

Japan, China, South Korea, India, and Australia are the worst-hit countries due to the rising number of COVID-19 cases and related deaths. The economies of India, China, Japan, and South Korea, among others, were hit badly with negative inflation, GDPs, and rising unemployment rates due to the COVID-19 pandemic. The effects of the COVID-19 pandemic have put health data sharing and interoperability under the microscope. The interruptions in supply chains and the massive demand for the efficient treatment of COVID-19 patients have raised critical challenges in the health research industry in Asia Pacific. It has also affected manufacturing, supply chain, and business and financial markets. Medical device manufacturers and suppliers are shifting their focus to developing and supplying COVID-19 essentials and medical devices for respiratory diseases, which affect the operations of the various key players operating in this region. The prevalence of thromboembolism differs significantly between different ethnic and population groups. In Japan, the incidence of VTE is reportedly about one-eighth of North Americans. Hyperhomocysteinemia and elevated levels of Factors I, VIII, and XI are the other possible hereditary risk factors. However, the differences are due to the lack of well-designed studies and non-standardized survey designs. The incidence of VTE in Asian countries has doubled in the past decade. This could be attributed to lifestyle changes, the aging population, and increasing awareness of VTE. Thromboembolism in COVID-19 patients are a major concern for clinicians. A Chinese study conducted on COVID-19 ICU patients reported 46–85.4% DVT incidence. China is expecting a remarkable recovery for NMH, with the resumption of trade operations after the relaxation of lockdown. A review of this list by regulator in China was expected in 2020 but has been practically delayed due to the COVID-19 pandemic.

The Asia Pacific low molecular weight heparin market is segmented into product type, packaging, application, end user and country. The Asia Pacific low molecular weight heparin market, based on product type, has been segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. The Asia Pacific low molecular weight heparin market based on packaging is segmented into multi-vials and prefilled syringes. In 2021, the multi-vials segment held the largest share of the market. The Asia Pacific low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. The Asia Pacific low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. Similarly, based on country, the market is bifurcated into China, Japan, India, Australia, South Korea, and rest of Asia Pacific. China held the largest share of the Asia Pacific low molecular weight heparin market in 2021. 

Abbott, Aspen Holdings, B. Braun Medical Inc., Changzhou Qianhong Biopharma Co Ltd, Dr. Reddy's Laboratories, LEO Pharma A/S, Novartis, Pfizer Inc., Sanofi, and TEVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies in the Asia Pacific Low Molecular Weight Heparin Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2018, of the phase two of pharmaceuticals production facility at Changzhou National Hi-Tech District on November 28. With an investment of 1 billion-yuan, phase two adds 200 million tablets and 60 million injections to production as well as making molecular diagnosis reagents available for use by 20 million people.

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

Download Free PDF Brochure